Trials / Unknown
UnknownNCT02943798
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.
Detailed description
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma. In addition, gene spectrum detection and Mini-PDX are applied for validation of pharmacodynamic. Results of clinical trials and pharmacodynamic test will be analyzed to provide evidence for the precise treatment for LCNEC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etoposide plus carboplatin | etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle. |
| DRUG | Paclitaxel plus carboplatin | Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2016-10-25
- Last updated
- 2016-10-25
Source: ClinicalTrials.gov record NCT02943798. Inclusion in this directory is not an endorsement.